Cagrilintide
A long-acting amylin analog developed to be combined with semaglutide for enhanced weight loss (CagriSema).
Overview
Cagrilintide is a synthetic amylin analog with a half-life that supports weekly dosing. Designed by Novo Nordisk to pair with semaglutide as 'CagriSema,' it represents a new class of metabolic peptides that complement GLP-1 therapy through a distinct mechanism.
Benefits
- Enhances satiety beyond GLP-1 alone
- Slows gastric emptying through amylin pathway
- Supports stronger weight loss in combination protocols
- Once-weekly administration
Mechanism of Action
Activates amylin and calcitonin receptors, suppressing appetite and food intake while slowing gastric emptying through pathways distinct from — and additive to — GLP-1.
Dosage (informational only)
- Typical range
- 0.16–2.4 mg per week (trial range)
- Frequency
- Weekly subcutaneous administration
Currently investigational. Most studied as a combination therapy alongside semaglutide.
Side Effects
- Nausea and vomiting
- Decreased appetite
- Possible injection site reactions
Related peptides
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.
A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.